» Articles » PMID: 12223124

The Role of Oestrogen and Progesterone Receptors in Human Mammary Development and Tumorigenesis

Overview
Specialty Oncology
Date 2002 Sep 12
PMID 12223124
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

A relatively small number of cells in the normal human mammary gland express receptors for oestrogen and progesterone (ER and PR), and there is almost complete dissociation between steroid receptor expression and proliferation. Increased expression of the ER alpha (ERalpha) and loss of the inverse relationship between receptor expression and proliferation occur at the very earliest stages of tumorigenesis, implying that dysregulation of ERalpha expression contributes to breast tumour formation. There is evidence also for alterations in the ratio between the two PR isoforms in premalignant breast lesions. Elucidation of the factors mediating the effects of oestradiol and progesterone on development of the normal breast and of the mechanisms by which expression of the ERalpha and the PR isoforms is controlled could identify new targets for breast cancer prevention and improved prediction of breast cancer risk.

Citing Articles

Identification of Novel Progesterone Receptor (PR) Inhibitors () from Metabolites of Biotransformation Fungal: A Bioinformatics Approach.

Dourado J, Lopes S, Jimenez D, Ramos R, Ferreira I Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005951 PMC: 11858247. DOI: 10.3390/ph18020136.


Progesterone receptor is constitutively expressed in induced Pluripotent Stem Cells (iPSCs).

Manganelli M, Mazzoldi E, Ferraro R, Pinelli M, Parigi M, Aghel S Stem Cell Rev Rep. 2024; 20(8):2303-2317.

PMID: 39168923 PMC: 11554879. DOI: 10.1007/s12015-024-10776-6.


Canine Mammary Tumors as a Potential Model for Human Breast Cancer in Comparative Oncology.

Razavirad A, Rismanchi S, Mortazavi P, Muhammadnejad A Vet Med Int. 2024; 2024:9319651.

PMID: 38766503 PMC: 11101259. DOI: 10.1155/2024/9319651.


Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study.

Gernier F, Grellard J, Dupont C, Castel H, Fernette M, Lahaye F BMC Cancer. 2023; 23(1):736.

PMID: 37559004 PMC: 10413707. DOI: 10.1186/s12885-023-11242-1.


Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.

Akhtar M, Akhter N, Talat A, Alharbi R, Sindi A, Klufah F Oncotarget. 2023; 14:528-541.

PMID: 37235839 PMC: 10219660. DOI: 10.18632/oncotarget.28442.


References
1.
Lawson J, Field A, Champion S, Tran D, Ishikura H, Trichopoulos D . Low oestrogen receptor alpha expression in normal breast tissue underlies low breast cancer incidence in Japan. Lancet. 1999; 354(9192):1787-8. DOI: 10.1016/s0140-6736(99)04936-3. View

2.
Shoker B, Jarvis C, Sibson D, Walker C, Sloane J . Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol. 1999; 188(3):237-44. DOI: 10.1002/(SICI)1096-9896(199907)188:3<237::AID-PATH343>3.0.CO;2-8. View

3.
Shoker B, Jarvis C, Clarke R, Anderson E, Hewlett J, Davies M . Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol. 1999; 155(6):1811-5. PMC: 1866935. DOI: 10.1016/S0002-9440(10)65498-3. View

4.
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R . Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000; 283(4):485-91. DOI: 10.1001/jama.283.4.485. View

5.
Ross R, Paganini-Hill A, Wan P, Pike M . Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000; 92(4):328-32. DOI: 10.1093/jnci/92.4.328. View